Accuray Incorporated

LSE:0H8I Stock Report

Market Cap: US$162.8m

Accuray Valuation

Is 0H8I undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0H8I when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$7.16
Fair Value
78.2% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: 0H8I ($1.56) is trading below our estimate of fair value ($7.16)

Significantly Below Fair Value: 0H8I is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0H8I?

Key metric: As 0H8I is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0H8I. This is calculated by dividing 0H8I's market cap by their current revenue.
What is 0H8I's PS Ratio?
PS Ratio0.3x
SalesUS$465.25m
Market CapUS$162.76m

Price to Sales Ratio vs Peers

How does 0H8I's PS Ratio compare to its peers?

The above table shows the PS ratio for 0H8I vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.8x
AOTI AOTI
2x21.37%UK£87.7m
EKF EKF Diagnostics Holdings
2.3x6.76%UK£113.7m
NIOX NIOX Group
6.4x10.78%UK£266.7m
CREO Creo Medical Group
12.6x12.49%UK£50.3m
0H8I Accuray
0.3x-1.12%US$162.8m

Price-To-Sales vs Peers: 0H8I is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (5.8x).

Price to Sales Ratio vs Industry

How does 0H8I's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.5x6.1%
0H8I Accuray
 0.3x-1.12%US$162.76m
SPEC INSPECS Group
0.2x4.30%US$63.57m
IHC Inspiration Healthcare Group
0.5x12.57%US$23.66m
0H8I 0.3xIndustry Avg. 2.5xNo. of Companies5PS02.44.87.29.612+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.5x18.5%
0H8I Accuray
 0.3x32.96%US$162.76m
No more companies

Price-To-Sales vs Industry: 0H8I is good value based on its Price-To-Sales Ratio (0.3x) compared to the UK Medical Equipment industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is 0H8I's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0H8I PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: 0H8I is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0H8I forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.55
US$5.63
+263.04%
17.07%US$7.00US$4.50n/a4
May ’26US$1.35
US$5.88
+336.80%
12.59%US$7.00US$5.00n/a4
Apr ’26US$1.79
US$6.13
+243.14%
8.90%US$7.00US$5.50n/a4
Mar ’26US$1.96
US$6.13
+212.50%
8.90%US$7.00US$5.50n/a4
Feb ’26US$2.23
US$6.13
+174.91%
8.90%US$7.00US$5.50n/a4
Jan ’26US$1.95
US$6.13
+213.99%
8.90%US$7.00US$5.50n/a4
Dec ’25US$2.24
US$6.13
+173.19%
8.90%US$7.00US$5.50n/a4
Nov ’25US$1.86
US$6.13
+229.30%
8.90%US$7.00US$5.50n/a4
Oct ’25US$1.84
US$6.13
+233.79%
8.90%US$7.00US$5.50n/a4
Sep ’25US$2.14
US$6.13
+186.89%
8.90%US$7.00US$5.50n/a4
Aug ’25US$1.88
US$6.00
+219.27%
11.79%US$7.00US$5.00n/a4
Jul ’25US$1.78
US$6.00
+238.03%
11.79%US$7.00US$5.00n/a4
Jun ’25US$1.73
US$6.00
+247.02%
11.79%US$7.00US$5.00n/a4
May ’25US$2.16
US$8.75
+305.26%
30.64%US$13.00US$6.00US$1.354
Apr ’25US$2.49
US$8.75
+251.52%
30.64%US$13.00US$6.00US$1.794
Mar ’25US$2.64
US$8.75
+231.34%
30.64%US$13.00US$6.00US$1.964
Feb ’25US$2.52
US$8.67
+244.60%
35.67%US$13.00US$6.00US$2.233
Jan ’25US$2.83
US$8.50
+200.45%
31.68%US$13.00US$6.00US$1.954
Dec ’24US$2.48
US$8.50
+242.88%
31.68%US$13.00US$6.00US$2.244
Nov ’24US$2.54
US$8.30
+226.77%
29.41%US$13.00US$6.00US$1.865
Oct ’24US$2.73
US$8.30
+203.92%
29.41%US$13.00US$6.00US$1.845
Sep ’24US$2.97
US$8.30
+179.65%
29.41%US$13.00US$6.00US$2.145
Aug ’24US$4.21
US$8.30
+97.38%
29.41%US$13.00US$6.00US$1.885
Jul ’24US$3.82
US$8.30
+117.56%
29.41%US$13.00US$6.00US$1.785
Jun ’24US$3.50
US$8.30
+137.48%
29.41%US$13.00US$6.00US$1.735
May ’24US$3.25
US$8.30
+155.78%
29.41%US$13.00US$6.00US$2.165
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
US$5.59
Fair Value
72.1% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 00:02
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Accuray Incorporated is covered by 22 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesBrean Capital
Neil ChatterjiB. Riley Securities, Inc.
Marie ThibaultBTIG